PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling by unknown
Ferreira et al. BMC Cancer 2012, 12:507
http://www.biomedcentral.com/1471-2407/12/507RESEARCH ARTICLE Open AccessPCA3 noncoding RNA is involved in the control of
prostate-cancer cell survival and modulates
androgen receptor signaling
Luciana Bueno Ferreira1,6, Antonio Palumbo2,6, Kivvi Duarte de Mello1,6, Cinthya Sternberg1,6, Mauricio S Caetano1,6,
Felipe Leite de Oliveira2,6, Adriana Freitas Neves3,6, Luiz Eurico Nasciutti2,6, Luiz Ricardo Goulart3,4,6
and Etel Rodrigues Pereira Gimba1,5,6,7*Abstract
Background: PCA3 is a non-coding RNA (ncRNA) that is highly expressed in prostate cancer (PCa) cells, but its
functional role is unknown. To investigate its putative function in PCa biology, we used gene expression
knockdown by small interference RNA, and also analyzed its involvement in androgen receptor (AR) signaling.
Methods: LNCaP and PC3 cells were used as in vitro models for these functional assays, and three different siRNA
sequences were specifically designed to target PCA3 exon 4. Transfected cells were analyzed by real-time qRT-PCR
and cell growth, viability, and apoptosis assays. Associations between PCA3 and the androgen-receptor (AR)
signaling pathway were investigated by treating LNCaP cells with 100 nM dihydrotestosterone (DHT) and with its
antagonist (flutamide), and analyzing the expression of some AR-modulated genes (TMPRSS2, NDRG1, GREB1, PSA,
AR, FGF8, CdK1, CdK2 and PMEPA1). PCA3 expression levels were investigated in different cell compartments by
using differential centrifugation and qRT-PCR.
Results: LNCaP siPCA3-transfected cells significantly inhibited cell growth and viability, and increased the
proportion of cells in the sub G0/G1 phase of the cell cycle and the percentage of pyknotic nuclei, compared to
those transfected with scramble siRNA (siSCr)-transfected cells. DHT-treated LNCaP cells induced a significant
upregulation of PCA3 expression, which was reversed by flutamide. In siPCA3/LNCaP-transfected cells, the
expression of AR target genes was downregulated compared to siSCr-transfected cells. The siPCA3 transfection also
counteracted DHT stimulatory effects on the AR signaling cascade, significantly downregulating expression of the
AR target gene. Analysis of PCA3 expression in different cell compartments provided evidence that the main
functional roles of PCA3 occur in the nuclei and microsomal cell fractions.
Conclusions: Our findings suggest that the ncRNA PCA3 is involved in the control of PCa cell survival, in part
through modulating AR signaling, which may raise new possibilities of using PCA3 knockdown as an additional
therapeutic strategy for PCa control.
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The noncoding RNA PCA3, which was initially charac-
terized as Differential Display Code 3 (DD3), is
prostate-tissue-specific and highly overexpressed in
more than 95% of primary prostate cancers [1]. PCA3
expression has shown promising applications for PCa
diagnosis in urine samples after intense prostate mas-
sage [2,3], and also in blood and tissue samples [2,4,5].
Combining PCA3 with other new biomarkers further
improves diagnostic and prognostic accuracy [6-9].
The specific activity of the PCA3 promoter in PCa
cells may also be used as an additional strategy for tar-
geted therapeutic approaches [10].
The gene encoding PCA3 is located on chromosome
9q21-22 in antisense orientation within intron 6 of the
Prune homolog 2 gene (PRUNE2 or BMCC1) [11].
Further characterization of the PCA3 transcript se-
quence revealed alternative splicing and alternative
polyadenylation, and due to a very short open reading
frame, it was designated as a non-coding RNA
(ncRNA) [1].
The PCA3 polyadenylation and its nuclear expres-
sion pattern support the hypothesis of a functional
role in prostate biology [12]. However, other investiga-
tors have pointed out that PCA3 is also expressed in
the cytoplasm of tumor cells and is not expressed in
the stromal compartment [13]. The upregulation of
PCA3 expression in PCa tissues seems to be an early
event in prostate-tumor development, since its expres-
sion has been observed in almost all types of PCa tis-
sue samples that have been analyzed, including well-
differentiated, moderately differentiated, and poorly
differentiated tumors [1]. Additionally, PCA3 expres-
sion seems to be restricted to cell lines that express
androgen receptor (AR), such as LNCaP cells [14]. Al-
though broadly characterized as a PCa specific bio-
marker, to our knowledge, data on the roles of PCA3
in PCa biology and tumor progression have not yet
been provided.
Many ncRNAs are highly expressed and specifically
regulated in tumors, which argues in favor of their func-
tional significance. MicroRNAs are the best-known
ncRNAs, although many other long ncRNAs exist. Differ-
ent approaches have been used to investigate the putative
biological roles of ncRNAs, including transcript overex-
pression, mutagenesis, DNA/RNA ChiP and gene knock-
down techniques. Among these, in vitro and in vivo gene
knockdown approaches, such as antisense oligonucleo-
tides and RNA interference, are the main strategies used
to investigate the roles of ncRNAs [15]. Herein, by using
small interfering RNA to knock down PCA3 gene expres-
sion in PCa cells, we provided evidence that PCA3 is
involved in PCa cell survival, which may be partially
modulated by the androgen-receptor pathway.Methods
Cell culture
LNCaP and PC3 prostate-cancer cell lines were
obtained from ATCC (Rockville, MD, USA) and main-
tained in RPMI-1640 medium (Sigma) supplemented
with 10% heat-inactivated fetal bovine serum (FBS)
(Invitrogen/Life Technologies, Inc.). The RWPE-1 non-
tumorigenic immortalized prostate cell line was a gener-
ous gift from Dr. Carlos Moreno (Emory University,
USA) and was maintained in Keratinocyte-Serum-Free
(KSF) (Invitrogen) supplemented with EGF (epidermal
growth factor) and BPE (bovine pituitary extract). The
PrEC, a non-tumoral primary prostate cell line (Cam-
brex BioScience, Walkersville, MD, USA) was main-
tained in PrEGMTM Prostate Epithelial Cell Growth
Medium according to the supplier’s protocol. The
DU145 cell line was obtained from ATCC and main-
tained in Dulbecco's Modified Eagle's Medium
(DMEM) (Invitrogen) with 10% FBS. HeLa and
NIH3T3 cell lines were cultured in DMEM containing
10% FBS. All these cell lines, except PrEC, were cul-
tured in the presence of 100 U/mL penicillin and 100
μg/mL streptomycin. Cell cultures were maintained at
37°C in a 5% CO2 humidified incubator. Primary pros-
tate stromal cells were isolated and characterized as
follows. Transurethral resection fragments of prostate
tissues obtained from three PCa surgeries were used to
obtain the stromal cells. This procedure was approved
by the Ethics Committee of Clementino Fraga Filho
University Hospital, Federal University of Rio de
Janeiro, and registered under protocol-CAAE
0029.0.197.000-05. Fragments of 1 to 3 mm3 were
grown in 24-well plates containing DMEM (Sigma)
culture medium supplemented with 10% FBS and
standard antibiotics. The medium was changed every
two days. After the cells attached to the bottom of the
culture plate, they were trypsinized and then trans-
ferred to 25 mm2 culture dishes. After six passages, a
homogeneous stromal cell population was established.PCA3 Expression knockdown by siRNA
Small interfering RNAs targeting the exon 4 of the
PCA3 ncRNA (siPCA3) and a scramble siRNA sequence
(siScR) were designed and synthesized by IDT Tech-
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use. On the day before transfection, LNCaP cells were
plated in 2.0 mL of RPMI without antibiotics and sup-
plemented with 0.5% FBS at a density of 2.5 × 105
cells/6-well dishes. After 24 h, 500 μL of RPMI
medium in each well was replaced by a combination
of 60 nM siRNA solution, OPTi-MEM and Lipofecta-
mine 2000 (Invitrogen), as described elsewhere [16].
The cells were maintained in culture for 36 h, and
PCA3 knockdown expression was analyzed by real-
time qRT-PCR, using 510R and 69F oligonucleotide
sequences (Table 1).
Preliminary analysis of siPCA3/1 and siPCA3/3
demonstrated lower efficiencies for PCA3 knockdown in
LNCaP cells after 36 h post-transfection (Figure 1B),
compared to the siPCA3/2. Therefore, due to the higher
siPCA3/2 efficiency in PCA3 silencing, all the remaining
experiments were subsequently performed with the
siPCA3/2, which is here termed siPCA3.Table 1 Oligonucleotide primers used for analysis of
RT-PCR and qRT-PCR expression of androgen
receptor-responsive genes and PCA3 transcript























PCA3 : 69-F AGATTTGTGTGGCTGCAGC
PCA3 : 510-R TCCTGCCCATCCTTTAAGG
*Also shown are the oligonucleotides used for analysis of constitutive gene
expression.Total RNA isolation and reverse transcription
Total RNA from all cultured cells was purified with the
RNeasy Mini Kit (Qiagen) and treated with RNase-free
DNase (Qiagen) during the RNA purification process.
One microgram of RNA was reverse-transcribed using a
“Superscript II First-Strand Synthesis System for RT-
PCR” cDNA Synthesis kit (Invitrogen).
Quantitative real-time PCR
Quantitative real-time PCR (qRT-pCR) was performed
using a CFX96 Real-Time System (BIORAD) C1000
Thermal Cycler, the cDNA from all cultured cells, and
Sybr Green (Applied Biosystems) as fluorophore, fol-
lowing the manufacturer’s instructions. Oligonucleotide
primers used for qRT-PCR are listed in Table 1. The
expression levels of ncRNA PCA3 and GAPDH,
TMPRSS2, NDRG1, GREB1, PSA, AR, FGF8, CdK1,
CdK2 and PMEPA1 mRNA levels were normalized
based on the reference gene, to 18S rRNA, using the
ΔΔCT. Conditions for PCR amplification were as follows:
50°C (2 min), 94°C (5 min) followed by 40 cycles at 94°C
(30 s), 50°C (30 s) 72°C (45 s), and a final extension at
72°C (15 min). To evaluate the specificity of PCR pro-
ducts, a melting curve analysis was performed after each
reaction.
Cell growth and viability assays
Cell growth was analyzed by crystal violet staining after
transfection of LNCaP, PC3, NIH3T3 and HeLa cells
with siPCA3 and siScr, and the viability of LNCaP and
PC3 cells was evaluated by trypan blue staining exclusion
assay. The crystal violet assay was conducted by fixing
cells in ethanol for 10 min, staining with 0.05% crystal
violet for 10 min, and solubilizing with methanol. The
supernatant was collected and its absorbance measured
in an ELISA reader (BIO-RAD iMARKE) at 595 nm.
LNCaP cells were pelleted by centrifugation and resus-
pended in 300 μL of phosphate-buffered saline (PBS, 1x
solution) for viability analysis. Trypan blue (0.4% in PBS;
10 μL) was added to a 10 μL aliquot of cell suspension,
and the number of viable unstained cells was counted
using a haemocytometer.
Cell cycle analysis
The cell cycle was analyzed by quantifying the amount
of stained DNA with flow cytometry after transfection
of LNCaP cells with siPCA3 and siScr. Approximately
2.5 × 105 cells were incubated with 60 nM siPCA3 or
siScr at the indicated time points. Cells were collected
and resuspended in 200 μL of propidium iodide solu-
tion (PBS, 0.1% Triton X-100, 0.1% RNase, and 50 μg/mL
propidium iodide; Sigma) and incubated for 5 min on ice.
Cells were run on a BD FACSCalibur flow cytometer
system (Becton Dickinson, Franklin Lakes, NJ, USA)
Figure 1 Analysis of gene expression of PCA3 transcript in different cell lines and its targeted knockdown by siPCA3 in PCa cells.
(A) RNA expression of PCA3 was quantified by qRT-PCR in different prostate (LNCaP, PrEC, RWPE-1, DU145, and PC3) and non-prostate cell lines
(NIH3T3 and HeLa). PCA3 expression was determined using the oligonucleotide primers described in the Methods section. PCA3 relative
expression levels were determined in each cell line and compared to PCA3 expression in the DU145 cell line, used as a reference in this assay.
(B) PCA3 expression was evaluated in LNCaP cells after knockdown using three different siPCA3 RNA sequences, termed siPCA3/1, siPCA3/2, and
siPCA3/3. PCA3 expression was evaluated at 36 h post-transfection, and its relative expression level was determined compared to LNCaP cells
transfected with the siSCr sequence, used as a negative control in this assay. (C) Following transfection of LNCaP cells with siPCA3/2, transcript
levels were evaluated by qRT-PCR assays at the indicated time points. PCA3 relative expression is shown compared to siScr/LNCaP transfected
cells. (D) PC3 cells were also transfected with siPCA3/2, and PCA3 expression was evaluated by qRT-PCR after 36 h post-transfection. 18S RNA was
used as a constitutive gene. Data are shown as mean ± SD. All experiments were biological replicates, repeated a minimum of three times.
**, p < 0.0017 and *** p < 0.0008.
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were obtained and analyzed with Cell-Quest 3.0.1
(Becton Dickinson, Franklin Lakes, NJ, USA) software.
DAPI staining assay
LNCaP cells were plated in 2.0 mL of RPMI without
antibiotics at a density of 2.5 × 105 cells/6-well dishes
containing a coverslip. After 24 h, 500 μL of RPMI
medium of each well was replaced by a combination of
60 nM siRNA solution, OPTi-Mem, and Lipofectamine
2000 (Invitrogen). The medium was replaced after 8 h
by 2.0 mL of RPMI containing 10% FBS and antibiotics
(100 U/mL penicillin and 100 μg/mL streptomycin). The
cells were maintained in culture for 36 h. Apoptotic cells
were identified by the appearance of pyknotic nuclei.
Morphological changes were determined by DAPI (4',6-
diamidino-2-phenyl-indole, Molecular Probes, Eugene,OR, USA) staining. On the coverslips, 36 h after siPCA3
or siScr-LNCaP transfection, cells were fixed with 4%
methanol-free formaldehyde solution for 30 min. Then,
mounting medium with DAPI was dispersed over the
entire slide section. Mounted slides were stored at 4°C
without light. Each slide was observed under a 4.0 fluor-
escence microscope at 100x magnification.
Androgen stimulation procedures
LNCaP cells were plated in 2.0 mL of RPMI without
antibiotics at a density of 1.5 × 105 cells/6-well dishes,
and maintained in medium containing charcoal/dextran
stripped FBS (CCS) (Invitrogen) for 3 days before treat-
ment with dihydrotestosterone (DHT), flutamide, or the
control vehicle (ethanol). DHT (Sigma, St. Louis, MO,
USA) was dissolved in absolute ethanol at a concentra-
tion of 1 M and reconstituted in culture medium at a
Ferreira et al. BMC Cancer 2012, 12:507 Page 5 of 15
http://www.biomedcentral.com/1471-2407/12/507concentration of 100 nM in 0.5% ethanol. Culture
medium containing 100 nM flutamide and 0.5% ethanol
(Sigma, St. Louis, MO, USA) was prepared using the
same procedure. The control medium contained only
0.5% ethanol. LNCaP cells were plated into 6-well cul-
ture plates and grown for 12 or 48 h before treatments
with DHT or DHT plus 100 nM flutamide. Flutamide
was added to cells 15 min before the 100 nM DHT
treatment. LNCaP cells were grown until the indicated
time points, and then cells were harvested for analysis of
PCA3 expression. For the analysis of expression of
androgen-regulated genes (PCA3, AR, PSA, TMPRSS2,
NDRG1, GREB1, FGF8, CdK1, CdK2 and PMEPA1),
LNCaP cells were seeded into 6-well culture plates and
grown for 36 h before the 100 nM DHT treatment. For
the simultaneous stimulation with DHT and PCA3 silen-
cing by siPCA3, LNCaP cells were maintained in CCS
for 3 days before siPCA3 transfections, and DHT (100
nM) was added to the LNCaP cells after 6 h. siPCA3
transfections were prepared according to the conditions
previously described for PCA3 knockdown by siPCA3.
Finally, at 36 h after transfection, the LNCaP cells were
harvested for analysis of gene expression.
Cell fractionation
siRNAs transfected LNCaP cells (1 × 107) were lysed
with liquid nitrogen and homogenized in a 0.25 M
sucrose solution buffered to pH 7.4 with 5 mM Tris–HCl.
The homogenate was centrifuged as described elsewhere
[17] to obtain four pellets (P1, P2, P3 and P4), which sedi-
mented respectively at 300 × g (5 min), 1000 × g (10 min),
8000 × g (10 min) and 100,000 × g (60 min). Fraction P1
contained mainly nuclei and some vesicles. Fraction P2
also contained nuclei, mitochondria, dense bodies, and
vesicles. Fraction P3 contained mainly mitochondria, with
a few vesicles and dense bodies. Finally, fraction P4 con-
tained free vesicles and microsomes. The pellets were
resuspended individually in buffered sucrose solution and
stored at - 15°C until use.
Preparation of cell lysates and immunoblot
Extracts of cells transfected with siPCA3 and siScr were
prepared with Cell Lysis Buffer (Cell Signaling Technol-
ogy), sonicated, and cleared by centrifugation at
15,000 × g. Total protein concentration was measured
using the BCA assay kit (BioRad), according to the man-
ufacturer’s instructions. LNCaP cells transfected with
siPCA3 and siScr control were cultured as previously
described. Immunoblot was performed using 50 μg of
protein extracts. PI3-Kinase activation was analyzed by
the levels of Akt Ser473 phosphorylation, and Erk1/2 ac-
tivation was analyzed by the levels of Thr202/Tyr204
phosphorylation. Membranes were incubated with anti-
total Akt and Erk1/2, anti-phospho-Akt antibodies, andanti-phospho-Erk1/2 (Cell Signaling Technology). Horse-
radish peroxidase (HRP)-conjugated anti-rabbit IgG
(Pierce, Rockford, IL, USA) was diluted 1:1000 in PBST
containing 5% bovine serum albumin. Chemiluminescence
detection (Amersham Biosciences, USA) was performed
according to the manufacturer’s instructions.
Statistical analysis
Results are presented as the mean +/- standard deviation
of at least three independent experiments. Differences
among groups were evaluated by Student’s t-test, using
GraphPad Prism software (San Diego, CA, USA). A
value of P < 0.05 was considered to be statistically
significant.
Results
Establishing a cell-line model to study the role of PCA3 in
PCa
In order to perform in vitro functional assays to deter-
mine the putative role of PCA3 in PCa, we first analyzed
the PCA3 transcript expression in different prostate
(LNCaP, PrEC, RWPE-1, DU145 and PC3) and non-
prostate (NIH3T3 and HeLa) cell lines. We analyzed the
PCA3 transcript levels in order to determine which was
the most appropriate model for further analysis. Consist-
ent with previous reports [1,14], we found that PCA3 is
highly expressed in the androgen-dependent prostate
cell line LNCaP (Figure 1A), compared to the prostate
cell lines PrEC, RWPE-1, PC3 and DU145. PCA3 ex-
pression was not detected in the non-prostate cell lines,
NIH3T3 and HeLa. Our data have indicated LNCaP cells
as the most suitable model to investigate the PCA3
function in PCa biology by using small interfering RNA
to silence this ncRNA, which was upregulated in these
cells when compared to other tested cells lines. We
tested on LNCaP cells, three different specific siRNAs
for PCA3, termed siPCA3/1, siPCA3/2, and siPCA3/3,
and evaluated their efficiencies for PCA3 knockdown.
Because of the significant effect on PCA3 silencing by
the siPCA3/2 (Figure 1B), we thereafter used this siRNA
(siPCA3) molecule to perform all the functional assays.
The PCA3 RNA levels decreased progressively from 24
h to 36 h post-transfection in the siPCA3/2-LNCaP
transfected cells, with a marked loss at 24 h (Figure 1C),
compared to the siScr-transfected LNCaP, used as a
negative control. The maximum loss of PCA3 expression
was observed at 36 h post-siPCA3 transfection. PCA3
expression was restored after 48 h post-transfection, in-
dicating siPCA3 withdrawal. We also evaluated the PC3
cell transfection with siPCA3, in order to determine the
effect of the PCA3 knockdown in a hormone-
independent PCa cell line, which shows lower levels of
PCA3 expression than the LNCaP cells. PCA3 expres-
sion of the PC3 cell line was also significantly inhibited
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further reinforce the effect of siPCA3 in silencing PCA3
expression, in both hormone-dependent and hormone-
independent cell lines.
PCA3 silencing decreases cell growth and survival and
induces apoptotic cell death in prostate-cancer cells
A number of hallmark events are associated with tumor
progression, of which apoptosis evasion and increased cell
proliferation are among the most critical ones. Our first ap-
proach to investigate the putative roles of PCA3 in PCa
biology was to determine LNCaP cell growth rates by using
crystal-violet assays over a 100-h time course after LNCaP
cell transfection with siPCA3 (Figure 2A). After 24 h,
siPCA3-transfected LNCaP cells progressively decreased
cell growth, compared to siScr-transfected LNCaP cells.
This decrease in cell growth was maintained until 50 h
post-siPCA3 treatment, when cell growth was restored,
possibly as a consequence of siPCA3 withdrawal, coin-
ciding with the PCA3 silencing expression profile
(Figure 1C). Interestingly, siScr-transfected LNCaP cells
showed no significant increase in cell growth during the
time-course evaluation, suggesting that the decreased cell
growth after PCA3 knockdown in siPCA3-transfected
cells may be due to an effect on cell viability rather than
on cell proliferation.
We then asked whether this observed decrease in cell
growth as a result of PCA3 silencing was specific forFigure 2 PCA3 knockdown inhibits LNCaP cell growth and survival. (A
non-targeting siRNA (siScr), and then followed for cell proliferation for 96 h
or non-targeting siRNA (siScr) and then followed for cell growth for 48 h. C
the Methods section. Data represent the mean ± SD of three independent
cell viability was measured using Trypan Blue exclusion analysis. Data are scells expressing PCA3 transcript, and also attempted to
exclude the possibility of siPCA3 off-target effects.
NIH3T3 and HeLa cells, which did not express PCA3
(as shown in Figure 1A), exhibited no change in cell
growth rates after siPCA3 transfection on a 60-h time
course evaluation (Figure 2B and 2C). These data further
indicated that PCA3 knockdown is specifically inhibiting
the growth rates of PCA3-expressing cells, and that the
siPCA3 molecule is specifically targeting PCA3.
We also observed that LNCaP cell viability was signifi-
cantly reduced in siPCA3-transfected LNCaP cells, com-
pared to siScr-transfected cells (Figure 2D), as measured
by trypan-blue exclusion assays at 36 h post-siRNA
transfection. Moreover, LNCaP-transfected cells with
either siPCA3 or siScr were monitored by flow cyto-
metry stained with propidium iodide, which allowed
the examination of intra-culture populations in differ-
ent cell cycle phases. LNCaP cells transfected with
siPCA3 showed a significant increase in the proportion
of cells in the G0 phase at 36 h post-transfection when
compared to siScr-LNCaP transfected cells (Figure 3A),
which is an indication of cells undergoing apoptosis.
Further evidence of apoptosis in siPCA3-transfected
cells was obtained by fluorescence microscopy after
DAPI DNA-staining (Figure 3B), which showed a
higher percentage of pyknotic nuclei in siPCA3-LNCaP
(9.04%) than in siScr-LNCaP cells (4.56%). Therefore,
the PCA3 knockdown in LNCaP cells may be) LNCaP cells were transfected with 60 nM of siPCA3 and
. (B) NIH3T3 and (C) HeLa cells were transfected with 60 nM of siPCA3
ell growth was evaluated using the crystal-violet assay described in
experiments (* p < 0.05). (D) The effect of PCA3 knockdown on LNCaP
hown as the mean ± SD of three experiments.
Figure 3 PCA3 knockdown induces cell cycle arrest and apoptosis in LNCaP cells. (A) Representative histograms of LNCaP cells 36 h
after transfection with siPCA3 or siScr (left panels). Flow cytometry was used to quantify the percentage of cells undergoing apoptosis
(cells in sub G0-G1), which are shown in the bar graph on the right panel. The data represent the means ± S.D. from three independent
experiments (right panel). The asterisks indicate significant differences between siPCA3 and siScr control-treated groups (*** p < 0.001).
(B) Nuclear morphological changes characteristic of apoptotic cells in LNCaP cell cultures transfected with siPCA3 or siScr (left panels) were
analyzed. A representative experiment is shown. Following fixation and staining with DAPI, LNCaP cells transfected with siPCA3 or siScr were
examined and photographed using a fluorescence microscope as described in the Methods section. The number of pyknotic nuclei in each
experimental sample was counted, and is represented on the bar graph in the right panel as the percentage of cells with pyknotic nuclei in
relation to the total number of cells counted. (C) Nuclear morphological changes characteristic of apoptotic cells in PC3 cell cultures transfected
with siPCA3 or siScr (left panels) were analyzed, and the results represented as described for LNCaP cells in (B). The data represent the
means ± S.D. from three independent experiments (right panel).
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apoptosis, and suggests that PCA3 may also be able to
modulate PCa cell survival. We also tested the effect
of PCA3 silencing on PC3 cell viability. These cells
also showed a significant increase in the percentage of
cells containing pyknotic nuclei, compared to siScr–
PC3 transfected cells (Figure 3C). These data further
reinforce the notion that PCA3 modulates PCa cell
survival, specifically of PCA3-expressing cells.PCA3 expression is upregulated by androgen-receptor
signaling, and modulates the expression of AR target
genes
Pro-survival signaling mediated by the androgen receptor
(AR) is implicated as a key contributor to prostate car-
cinogenesis, which classically controls PCa cell prolifera-
tion, survival, and differentiation [18,19]. Considering that
PCA3 expression is upregulated in androgen-dependent
cell lines, such as LNCaP cells, we investigated the
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survival signaling pathway.
To elucidate how PCA3 could be related to AR pro-
survival signaling, we first demonstrated the PCA3 ex-
pression response of LNCaP cells submitted to androgen
stimulation, and then the involvement of AR in this sig-
naling. Previous reports demonstrated that PCA3 ex-
pression is responsive to DHT stimulation [11,12,20].
However, it has not been clearly demonstrated whether
the activated AR mediates this androgen-responsive
PCA3 expression. We first evaluated PCA3 expression
levels in LNCaP cells treated with dihydrotestosterone
(DHT), the androgen active metabolite, for 48 h. Cor-
roborating other reports, we also found that DHT-
stimulated LNCaP cells significantly activated PCA3
expression (Figure 4A). To demonstrate that the upregu-
lated PCA3 expression was directly controlled by theFigure 4 PCA3 expression is upregulated by androgen and modulate
expression was evaluated in LNCaP cells by qRT-PCR after treatment with 1
time course, as described in the Methods section. PCA3 relative expression
was the control vehicle. Error bars +/- SD. (B) Relative RNA quantification o
PSA, AR, FGF8, CdK1, CdK2, and PMEPA1) in LNCaP cells treated with 100 n
with the control vehicle (ethanol), as described in the Methods section. Bar
qRT–PCR analysis of three independent RNA samples prepared following th
bars +/- SD. (C) Relative RNA levels of PCA3, AR, and androgen-regulated g
LNCaP/siSCr transfected cells. Error bars +/- SD. (D) Relative RNA levels of P
transfected with siPCA3 simultaneously with treatment with 100 nM DHT, c
treatment with 100 nM DHT, as described in the Methods section. 18S RNA
represented as mean ± SD. All experiments were biological replicates repe
scrambled-siRNA (siScr) treated cells.signal mediated by the activated AR, we treated these
cells with DHT together with an AR antagonist fluta-
mide. PCA3 upregulation evoked by DHT was reversed
by flutamide, since it competes with DHT for AR bind-
ing. These data demonstrated that PCA3 expression is
androgen-regulated via the activated AR-mediated signal.
The increased AR transcriptional activity was confirmed
by the upregulation of all AR-responsive genes after
DHT treatment, including the increased expression of
AR and PCA3 (Figure 4B). Although the upregulation
was not statistically significant for all genes tested, they
showed at least a 1.5-fold increase in their expression
levels when compared to non-DHT-treated LNCaP cells.
Five of the eight AR-responsive genes tested showed at
least a 3-fold increase in their expression levels after
DHT treatment. AR and PCA3 transcript expressions
were also upregulated in these experimental conditions.s the transcription of androgen-regulated genes. (A) PCA3
00 nM of DHT or 100 nM DHT plus 100 nM flutamide during a 48-h
was determined compared to LNCaP cells treated with ethanol, which
f PCA3, AR and androgen-regulated genes (TMPRSS2, NDRG1, GREB1,
M of dihydrotestosterone (DHT) for 36 h, compared to cells treated
graphs show the average transcript levels of each gene tested, by
e treatment of LNCaP cells with DHT or ethanol only. Error
enes 36 h after LNCaP cells were transfected with siPCA3, compared to
CA3, AR, and androgen-regulated genes 36 h after LNCaP cells were
ompared to LNCaP cells transfected with siScr simultaneously with
was used as a constitutive gene in all these assays. Data are
ated a minimum of three times. *, p < 0.01, in comparison to
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line expresses higher PCA3 levels than the other cell
lines tested, and that downregulation of this ncRNA sig-
nificantly decreases LNCaP survival, we then speculated
whether PCA3 silencing could modulate the expression
of AR target genes, and whether this event could be
related to the observed decrease in LNCaP survival.
LNCaP cells transfected with siPCA3 caused a significant
downregulation of seven of the eight AR-regulated genes
tested, compared to the cells transfected with siScr
(Figure 4C). Five of these downregulated genes showed a
statistically significant decrease in their expression levels
(p< 0.05): PSA, NDRG1, FGF8, CDK1, and PMEPA1.
Then, we analyzed the effect of PCA3 silencing together
with DHT stimulation. The upregulation of the AR target
genes triggered by the DHT treatment was reversed by
the concomitant PCA3 knockdown (Figure 4D). Six of
eight AR target genes tested showed at least a 40% de-
crease in their expression levels, including TMPRSSE2,
NDRG1, GREB1, FGF8, CDK2, and PMEPA1, although
this decrease was not statistically significant (p>0.05).
Both PCA3 and AR transcription levels were also down-
regulated in this condition. These results suggest that
PCA3 is somehow modulating the expression of AR
signaling, which should be further investigated. In
summary, our data suggest that the ncRNA PCA3 is
responsive to AR signaling and may act as a transcrip-
tional modulator of the AR target genes.
We also evaluated whether key mediators of signaling
pathways that cross-talk with the AR pathway were also
modified in siPCA3-LNCaP transfected cells. It is well
known that PI3K-Akt and MAPK signals mediate key
pro-survival roles in PCa cells, and that their phosphory-
lated forms are able to modulate AR activation and the
androgen-independent transcriptional activation of AR
target genes. Activation of these signals promotes the
phosphorylation of AR and its co-regulators, increasing
AR transcriptional activity and the expression of AR tar-
get genes involved in PCa pro-survival roles [21,22]. TheFigure 5 Downregulation of PCA3 expression does not
significantly reduce Akt and Erk1/2 phosphorylation in LNCaP
cells. The Akt and Erk1/2 phosphorylation profile before and after
transfection of LNCaP cells with either siPCA3 or siScr was
investigated by immunoblot analysis using 50 μg of total protein
extracts. Akt and Erk1/2 non-phosphorylated proteins were used as
controls for normalization of protein loading.phosphorylation status of Akt and ERK was tested in the
siPCA3-LNCaP cells, as representative genes of the
growth-factor signaling pathways that cross-talk with AR
signaling (Figure 5). We found that siPCA3-transfected
LNCaP cells did not modify Akt and ERK phosphoryl-
ation levels compared to siScr-transfected LNCaP cells,
suggesting that PCA3 may modulate LNCaP survival
mainly through downstream signals of the activated AR
signaling axis.
PCA3 is mostly expressed in nuclear and microsomal cell
compartments
As an additional approach to investigate the putative
roles of PCA3 in PCa cells, we determined the cell com-
partment localization of PCA3 in LNCaP cells by differ-
ential centrifugation and qRT-PCR. RNA was extracted
from different cell compartments obtained through dif-
ferential centrifugation, and PCA3 expression was ana-
lyzed. Our data showed that PCA3 expression was
mainly restricted to the nuclear and microsomal com-
partments (P1 and P3 fractions, respectively) of LNCaP
cells (Figure 6A). We also tested PCA3 expression in
primary prostate stromal cell cultures, which showed no
PCA3 expression (Figure 6B). Our results suggest that
the nuclear and microsomal cell compartments of
prostate-tumor epithelial cells are the major sites of
PCA3 expression, where PCA3 may play its main roles
in controlling PCa cell pro-survival features.
Discussion
The PCA3 ncRNA is one of the most prostate-specific
genes described to date, is highly overexpressed in PCa
tumors, and has been extensively characterized as a
tumor biomarker [1,2,4,7,23]. However, no function has
been attributed to this transcript in PCa cells
[1,2,4,7,23]. Our primary aim was to elucidate the puta-
tive roles of this ncRNA in PCa cell biology. Previous
data have partially supported the concept that PCA3 is a
functional transcript, as argued for other ncRNAs [1,12].
The limited expression of PCA3 in prostate tissues sug-
gests that it may function specifically in this organ. This
also suggests that its expression may be tightly regulated,
as would be expected for a functional transcript. The
results obtained here support the notion that PCA3 is
involved in PCa survival pathways by controlling cell
growth and viability, at least in part through controlling
the AR pro-survival signaling. In addition, our results
accord with the hypothesis that PCA3 is involved in
transcriptional modulation of AR target genes, although
it may act through a still-unknown mechanism.
Other ncRNAs have also been described as being
involved in cancer cell survival, including PlncRNA-1,
GAS5, HOTAIR, and several miRNA genes [24-27],
which act by controlling apoptosis, the cell cycle, cell
Figure 6 PCA3 is mostly expressed in LNCaP nucleus and microsomal cell fractions. (A) Total RNA samples obtained from different LNCaP
cell compartments. Fraction P1 contained mainly nuclei and some vesicles. Fraction P2 contained nuclei, mitochondria, dense bodies, and
vesicles. Fraction P3 contained mainly mitochondria, with a few vesicles and dense bodies. Finally, fraction P4 contained free vesicles and
microsomes. Bar graphs represent PCA3 ncRNA relative expression levels in each subcellular compartment, compared to total RNA from LNCAP
cell whole extracts, containing a mixture of RNA samples from all cell compartments. 18S rRNA was used as a constitutive gene. (B) Analysis of
PCA3 expression by RT-PCR in total RNA samples from primary prostate stromal cell cultures. M: molecular weight marker, 100 bp; Lane 1: Total RNA
samples from a single PCa tumor expressing PCA3; Lanes 2 – 4: Three different primary prostate stromal-cell cultures.
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intracellular signaling networks. Other ncRNAs involved
in PCa cell survival and proliferation have also been
described, including PCAT-1 [28], PRNCR1 [29],
PCGEM1 [30], and PlncRNA-1 [24]. Similarly to PCA3,
the AR signaling pathway also modulates the expression
of PRNCR1, PlncRNA-1, and PCGEM1. Additionally,
several androgen-responsive intronic ncRNAs have been
described, indicating that intronic ncRNAs, such as
PCA3 [31], may have control mechanisms that are com-
mon to protein-coding transcripts, such as those involv-
ing hormonal control of gene-promoter activation [32].
The facts that PCA3 is expressed in higher levels in the
androgen-responsive cell line (LNCaP) and that some
ncRNA expressed in PCa cells are involved in the AR sig-
naling [24,29,30] led us to hypothesize that PCA3 ncRNA
expression may also be modulated by this pathway, and
that this transcript may also be involved in the control of
genes related to this cell signaling.
Uncontrolled cell growth is a result of a progression of
changes at the cellular and genetic levels, which ultim-
ately reprogram a cell to undergo uncontrolled division,
and is one of the first steps in carcinogenesis. In order to
investigate the putative involvement of PCA3 in control-
ling this early step of tumorigenesis, we investigated the
behavior of LNCaP cell growth after PCA3 knockdown
by RNA interference. PCA3-silenced LNCaP cells
showed a significant attenuation of cell growth, with a
corresponding increase in the number of cells undergo-
ing apoptosis. Transfected cells with siScr also showed a
slight decrease in cell growth after 20 h post-transfection,
which could be due to a cytotoxicity effect promoted by
the lipofectamin transfection reagent and acting specific-
ally on LNCaP cells, which has not been observed inother cell lines. Notably, siPCA3-LNCaP transfected cells
show a greater decrease in cell growth rates than do
siScr-transfected cells, indicating that PCA3 ncRNA is
involved in PCa survival and that siPCA3 specifically tar-
geted PCA3 transcripts, since growth rates were not
modified in cells that do not express PCA3. Considering
that PCA3 is specifically expressed in prostate tissues [1],
it is possible that PCA3 silencing would be an interesting
therapeutic approach, especially to inhibit PCa growth
and progression, as has been proposed for other genes
involved in PCa survival [33,34]. The evidence presented
in this study, for a potential modulating role of PCA3 in
the AR signaling, highlights the importance of this tran-
script as a potential target for treatment. This may also
be an interesting approach during PCa progression, espe-
cially when androgen resistance is developed [35]. In
addition, PCA3 expression at different PCa stages [1]
further reinforces the notion that this ncRNA plays an
essential role during PCa tumorigenesis and progression.
In order to further emphasize the role of PCA3 in
modulating PCa cell survival, we also investigated the
effect of PCA3 knockdown in an androgen-independent
PCa cell line, which simulates a more aggressive PCa dis-
ease. However, conflicting results have been reported
regarding the androgen independence of these cells and
AR protein expression in the PC3 and DU145 cell lines,
as well in castration-resistant prostate cancer tumors
[36,37]. Although the majority of human prostate-cancer
cell lines are reported to be AR-negative [38,39], several
studies have indicated that the DU-145 and PC-3
prostate-cancer cell lines express detectable levels of the
AR mRNA [40-44]. For this reason, the exact role of AR
in PC3 cells is still controversial [36]. Although PC3 cells
showed lower PCA3 expression than did the LNCaP
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in these cells. Considering the heterogeneity of PCa
tumors regarding gene expression profiling and tumor
progression behavior, we then wanted to evaluate survival
features after PCA3 knockdown even in cell lines that
express low PCA3 levels, and that in principle are andro-
gen-independent. Since PC3 is a well-established cell-line
model representing a more aggressive stage of prostate
cancer tumors, our data provide additional evidence for a
role of PCA3 in modulating PCa cell survival. We also
wanted to investigate how these androgen-independent
cells would respond to PCA3 knockdown. Our results
demonstrated that PCA3 knockdown, as demonstrated
by the significant decrease in PCA3 levels after transfect-
ing PC3 cells with the siPCA3 molecule, increased the
proportion of cells with pyknotic nuclei (compared to
PC3 transfected with siScr control), which was indicative
of a larger number of cells undergoing apoptosis, further
evidencing the role of PCA3 in modulating PCa cell sur-
vival, even in an androgen-independent cell-line model
that expresses lower PCA3 levels compared to LNCaP
cells. However, how PCA3 can modulate PCa cell sur-
vival in these cells and whether it is mediated by different
mechanisms from those observed in siPCA3-LNCaP
transfected cells, should be further investigated.
Due to the increased PCA3 expression in androgen-
responsive cells compared with androgen-insensitive
cells [36], and because AR signaling is an important
pathway controlling PCa survival, we tested whether
PCA3 expression was modulated by the androgen-active
metabolite DHT and whether this expression pattern
involved the activated AR. Upregulation of PCA3 ex-
pression in response to LNCaP stimulation with DHT
was significantly counteracted by the AR antagonist flu-
tamide, indicating that PCA3 expression was induced by
the activated AR. AR activation was further confirmed
by the observation that LNCaP cells stimulated with
DHT also showed AR transcriptional activity. Consist-
ently, all of the AR target genes tested that contain
canonical AR response elements (AREs) in their pro-
moter sequences, were upregulated upon DHT treat-
ment. Although eight of the genes showed at least a
1.5-fold increase after AR activation, only two of them
showed a significant increase in their expression levels.
Interestingly, PCA3 upregulation upon DHT treatment
has been observed previously [11,20], but no study has
demonstrated the involvement of activated AR in PCA3
expression by using AR antagonists. Although our data
also suggest that PCA3 is an androgen-responsive gene,
the precise molecular mechanism by which PCA3 ex-
pression responds to this activation is still unknown.
One hypothesis is that activated AR can directly acti-
vate the PCA3 promoter, as has been demonstrated for
the miR-101 and miR-21 regulatory regions [45,46],which are also modulated by the activated AR. However,
no consensus AREs have been identified in the 500-bp
PCA3 promoter region [47]. We further screened for
consensus ARE elements in the entire PCA3 genomic re-
gion at the 5 Kb region upstream from the PCA3 tran-
scription start site, and have so far identified no
canonical element (data not shown). Nevertheless, we
cannot exclude the possibility that other, non-canonical
ARE elements could also promote AR binding and dir-
ectly activate PCA3 expression, as has been previously
described for other genes modulated by the AR activa-
tion [48,49]. PCA3-upregulated expression in response
to DHT treatment could also be a result of activated AR
binding to the regulatory regions of other AR-responsive
genes, which in turn could induce PCA3 expression. Fur-
ther experiments should investigate direct AR binding to
different PCA3 genomic regions, in order to answer
these open questions.
Our data support a pro-survival role for PCA3, since
its downregulation, in addition to inhibiting PCa sur-
vival, decreased the expression of AR target genes, most
of them typically involved in androgen-dependent cell
growth. The close association between the involvement
of PCA3 in PCa cell survival and the modulation of the
expression of AR should be further investigated, in an
attempt to elucidate how PCA3 expression levels can
regulate AR signaling and target genes. Furthermore,
PCA3 knockdown inhibited the expression of all AR
target genes tested, even under DHT treatment, indicat-
ing that the final effect of PCA3 downregulation may
be stronger than the effect of DHT stimulation in
modulating the expression of AR target genes. On the
other hand, Akt and ERK phosphorylation levels
remained unchanged in siPCA3-transfected cells, indi-
cating that alternative pathways able to activate AR ir-
respective of ligand activation [50] were not altered
after PCA3 knockdown. Taken together, these data sug-
gest that the role of PCA3 in modulating the expression
of these AR target genes may function downstream
from AR activation.
As an approach to investigate the signal by which
PCA3 controls PCa cell survival, we analyzed the tran-
script expression of PSA, AR, TMPRSS2, NDRG1,
GREB1, FGF8, CDK1, CDK2, and PMEPA1 genes, all of
which have key roles in PCa growth and progression,
and are classical AR target genes [51]. Also highly regu-
lated by androgens, fibroblast growth factor 8 (FGF8)
[52], cyclin-dependent kinase 1 (CDK1), cyclin-dependent
kinase 2 (CDK2) [53], and the gene regulated in breast can-
cer 1 (GREB1) [54] gene products have classical stimulat-
ing roles in prostate growth and proliferation. Conversely,
the PMEPA1 gene, although a direct transcriptional target
of the AR, has been described as a negative regulator of cell
growth in the prostate epithelium, as well as negatively
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[55,56]. We also observed that the AR transcription level
was downregulated after PCA3 knockdown. These results
accord with previously published data, which demon-
strated that the AR gene is transcriptionally regulated by
AR through binding to AR regulatory elements (autoregu-
lation). However, differently from the other AR-responsive
genes tested here, the ARE elements required for this
process have not been found in the AR promoter or in the
5'-flanking region, but rather in AR coding sequences [57].
Since DHT treatment also upregulated AR transcript
expression, it is possible that PCA3 could also modulate
the transcriptional activity of AR, as has been postulated
for other ncRNAs [58,59]. Although it shows both onco-
genic and tumor-suppressor roles, PSA also has key roles
in promoting tumor progression and metastasis [60].
NDRG1-ERG fusions, encoding a chimeric protein, are
also androgen-regulated and correspond to one of the re-
current erythroblast transformation-specific rearrange-
ments found in PCa samples. Presumably, NDRG1
participates in angiogenesis, metastasis, and mechanisms
leading to anti-cancer drug resistance [61]. TMPRSS2,
another component of these typical androgen-regulated
PCa translocations, is highly expressed in PCa cells, con-
tributing to prostate tumorigenesis [62,63]. The observed
downregulation of some of these tested AR target genes
after PCA3 silencing could be part of the events related
to inhibition of PCa cell survival, especially because some
of these genes are classical positive modulators of PCa
progression. Considering that some of the AR target
genes tested were downregulated by PCA3 knockdown,
we hypothesize that PCA3, similarly to other ncRNAs,
could be a key modulator of the AR signaling pathway, as
has been observed for other ncRNA gene products in
controlling key pathways [64]. However, highly aggressive
metastatic PCa cell lines that are termed AR-insensitive,
such as PC3 and DU145, only express PCA3 at very low
levels, indicating that PCA3 may play a role (in combin-
ation with other factors) by promoting the transition
from an AR-dependent to a hormone-refractory disease.
Data concerning the expression of AR in PC3 and
DU145 cells are contradictory. Although they are classic-
ally termed androgen non-responsive and AR-negative
cells, the expression of AR transcript and protein has
been clearly demonstrated in PC3 and DU145 cells, as
has been AR nuclear translocation, but not transcrip-
tional activity [36]. Because PCA3 silencing in PC3 cells
also inhibited PC3 viability, it is possible that PCA3 may
be involved in AR signaling at alternative steps that are
able to control the expression of AR-responsive genes in
an androgen-independent manner, as described for other
gene targets [65]. Notably, PC3 cells, although they
expressed lower PCA3 levels than LNCaP cells, showed
greater inhibition of cell survival after PCA3 silencing.Possibly, due to lower PCA3 levels in PC3 cells, silencing
of this transcript was more effective, with a stronger
negative effect on cell survival.
Based on these data, we suggest that PCA3 probably
behaves as a modulator of the expression of the AR tar-
get gene, although the underlying mechanism by which
PCA3 regulates the expression of these AR target genes
remains elusive. One hypothesis is that PCA3 long
ncRNA or its putative processed RNA products could
directly control the transcription of AR-regulated genes,
as has been reported for other ncRNAs [59,66]. It is also
possible that PCA3 transcripts could modulate the
transcriptional activity of AR-regulated genes by con-
trolling the interaction and/or expression of multiple
AR co-regulatory proteins, which facilitate the formation
of an active transcription complex to activate transcription
of AR target genes, similarly to what has been described
for the Steroid Receptor Coactivator (SRA), a non-coding
RNA that confers functional specificity during transcrip-
tional activation [67]. Inactive or under-represented co-
activators could not evoke AR binding to their cognate
binding sites on AR-responsive genes, promoting the
downregulation of these genes [68]. This possibility accords
with our data regarding the downregulation of the tested
AR target genes after PCA3 knockdown, indicating that a
key positive AR signal was disrupted. Furthermore, the
downregulation of these AR target genes occurred even in
LNCaP cells that were not DHT-activated, indicating that
the role of PCA3 in modulating the transcription of these
genes is independent of AR ligand activation. Our current
studies highlight the need for further investigation to elu-
cidate the exact mechanisms by which PCA3 controls
PCa cell survival and how it modulates AR signaling and
cell growth.
The subcellular location of ncRNAs has also provided
significant insights into their functions. We found in the
present study that PCA3 is mainly expressed in the
nuclear and microsomal subcellular fractions in LNCaP
prostate epithelial cells, but not in prostate-tumor stro-
mal cells. Contradictory findings regarding PCA3 expres-
sion have indicated that this transcript was restricted to
the nuclear [12] or cytoplasmic [13] cell compartments.
In order to clarify this, we used a cell-fractionated PCA3
transcript expression analysis approach, in which most
PCA3 transcripts were located in nuclear fractions, and
to a lesser extent in microsomal compartments, which
classically contain ribosomal and vesicle particles. Other
long non-coding RNAs have also been found in nuclear
fractions, especially accumulated in specific nuclear bod-
ies [69]. Other reports have also identified ncRNAs at
nuclear speckles, where these molecules could regulate
alternative splicing by modulating the activity of splicing
regulatory proteins [70]. Other roles described for
ncRNAs located in nuclear compartments, including
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tors and in chromatin remodeling, have been reviewed
elsewhere [71]. Co-purification with ribosomes has also
been described for other long ncRNAs, such as HULC,
implying that they play a role in translational control [72]
and in nonsense-mediated mRNA decay (NMD) [73].
The presence of PCA3 transcripts in both nuclear and
microsomal compartments may indicate that PCA3
could perform its main roles in both cell niches. These
data may help to direct our future approaches in
attempting to identify the exact roles of PCA3 in modu-
lating the transcription of AR target genes. Because
PCA3 is not expressed in stromal cells, it seems that its
role in controlling PCa cell survival may be restricted to
prostate epithelial cells and possibly their AR signaling
pathway.
Conclusions
Here we demonstrate for the first time that PCA3 is
involved in the control of PCa cell survival, at least in part
by modulating the transcriptional activity of AR target
genes. To our knowledge, this is the first characterization
of the functional role of PCA3 in PCa cells, and will not
only improve the understanding of key roles of this tran-
script in prostate carcinogenesis, but also suggests an al-
ternative strategy to use PCA3 as a putative specific
target for PCa treatment approaches. Because PCA3
seems to be a regulator of the expression of AR target
genes and PCa cell survival, treatment options aiming
to downregulate PCA3, in combination with other
androgen-depletion-based strategies, could potentially
circumvent androgen-ablation resistance mechanisms.
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